Antisoma's ASA404 enters pivotal phase III trial in second-line lung cancer
Antisoma plc announced that 'ATTRACT-2', a phase III trial testing ASA404 as a second-line treatment for non-small cell lung cancer (NSCLC), is now underway. This is a single pivotal study designed to support applications to market ASA404 for lung cancer patients who have received one previous round of treatment. A separate, ongoing pivotal trial, ATTRACT-1, is evaluating ASA404 in patients receiving their first treatment for NSCLC.
ATTRACT-2 (Anti-vascular Targeted Therapy: Researching ASA404 in Cancer Treatment-2) is a randomised, double-blind, placebo-controlled, multi-centre, multi-country phase III trial that will include approximately 900 patients receiving their second treatment for stage IIIb/IV NSCLC of either squamous or non-squamous histology. It is open to patients who previously received only chemotherapy and to patients who received chemotherapy plus bevacizumab or cetuximab as their first-line treatment. Patients will be randomly assigned to receive either ASA404 1800 mg/m2 plus docetaxel or a placebo plus docetaxel. The primary endpoint of the trial is overall survival. Before the final analysis there will be a single interim look, which is expected to occur during 2010. The study is expected to be completed in 2011.
ASA404 (DMXAA) is a small-molecule Tumour-Vascular Disrupting Agent (Tumour-VDA) which selectively targets the blood vessels that nourish tumours. The drug was discovered by Professors Bruce Baguley and William Denny and their teams at the Auckland Cancer Society Research Centre, University of Auckland, New Zealand. It was in-licensed by Antisoma from Cancer Research Ventures Limited (now Cancer Research Technology), the development and commercialisation company of the Cancer Research Campaign (now Cancer Research UK), in August 2001. Worldwide rights to the drug were licensed to Novartis AG in April 2007.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Activation against Malaria: Facile Oxidation of Leucomethylene Blue and Dihydroflavins by Artemisinins
Aragen Bioscience, Inc. and CEVEC Sign License Agreement for Human CAP and CAP-T Technology

Brain cancer cells hide while drugs seek - Tumor cells temporarily lose mutation to evade drugs targeting mutation
Biosciences' Nimotuzumab Selected for Multinational Phase III Trial by National Cancer Centre of Singapore - Singapore investigators to coordinate 700 patient trial of EGFR targeting antibody for treatment of head and neck cancer

Merck to Become First Provider to Offer Fully Integrated mRNA Services - New sites at Darmstadt and Hamburg complement Merck’s global integrated mRNA service network
FDA grants Orphan Drug Status for to-BBB’s lead product
Phase 2a Study of HIV-1 Investigational Maturation Inhibitor - Demonstration of positive results for therapy designed to attack virus in a new way
Oxyrane Raises $26.5m in Series D Financing

InfectoPharm invests in AudioCure to advance innovative hearing loss therapy - Drug candidate AC102 in the clinical phase
